David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
The current controversy as to the proper role of the placebo control in the evaluation of new treatments for schizophrenia requires an analysis that is sensitive to both ethical and scientific issues. Clinical equipoise, widely regarded as the moral foundation of the randomized controlled trial (RCT), requires the use of best available treatment as the control in RCT. Scientific criticisms of the use of an active control are examined and none present an insuperable barrier to the use of an active control. Indeed, scrutiny of the most recent argument for the use of placebo controls, 'assay sensitivity', suggests that the use of placebo may be the cause of the problem pointed to. Scientific, regulatory, ethical and legal advantages of the use of an active control are described. While the use of a placebo control may be acceptable in carefully defined circumstances, in most cases the use of an active control in schizophrenia research is ethically and scientifically preferable
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library||
References found in this work BETA
No references found.
Citations of this work BETA
No citations found.
Similar books and articles
Franklin G. Miller & Howard Brody (2002). What Makes Placebo-Controlled Trials Unethical? American Journal of Bioethics 2 (2):3 – 9.
Ernst A. Singer (2004). The Necessity and the Value of Placebo. Science and Engineering Ethics 10 (1):51-56.
James A. Anderson (2006). The Ethics and Science of Placebo-Controlled Trials: Assay Sensitivity and the Duhem-Quine Thesis. Journal of Medicine and Philosophy 31 (1):65 – 81.
Jacek Spławiński & Jerzy Kuźniar (2004). Clinical Trials: Active Control Vs Placebo — What is Ethical? Science and Engineering Ethics 10 (1):73-79.
Jeremy Sugarman (2004). Using Empirical Data to Inform the Ethical Evaluation of Placebo Controlled Trials. Science and Engineering Ethics 10 (1):29-35.
Bozidar Vrhovac (2004). Placebo and the Helsinki Declaration — What to Do? Science and Engineering Ethics 10 (1):81-93.
Mark D. Sullivan (1993). Placebo Controls and Epistemic Control in Orthodox Medicine. Journal of Medicine and Philosophy 18 (2):213-231.
Beatrice Alexandra Golomb (2009). Control Theory: Placebo-Controlled Drug Trials Have Problems. Active-Controlled Drug Trials Are Not Always the Solution. American Journal of Bioethics 9 (9):67-69.
Carlo Petrini (2009). Ethical Issues in the Difference Between Placebo-Controlled and Active-Controlled Trials. American Journal of Bioethics 9 (9):56-58.
Andrew Turner (2012). 'Placebos' and the Logic of Placebo Comparison. Biology and Philosophy 27 (3):419-432.
Thomas R. Weihrauch (2004). Placebo Treatment is Effective Differently in Different Diseases — but is It Also Harmless? A Brief Synopsis. Science and Engineering Ethics 10 (1):151-155.
T. M. Lemmens, P. S. Appelbaum, W. Carpenter, C. McCarthy, C. Peterson, D. Streiner & Charles Weijer, Placebo-Controlled Studies in Schizophrenia: Ethical and Scientific Perspectives. Panel Discussion.
Teresa Swift & Richard Huxtable (2013). The Ethics of Sham Surgery in Parkinson's Disease: Back to the Future? Bioethics 27 (4):175-185.
Piotr Zaborowski & Adam Górski (2004). Informed Consent and the Use of Placebo in Poland: Ethical and Legal Aspects. Science and Engineering Ethics 10 (1):167-178.
Added to index2010-09-08
Total downloads8 ( #168,292 of 1,098,601 )
Recent downloads (6 months)0
How can I increase my downloads?